Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15214887 | 0.98 | CYP3A4 (0.37) | NPSR1CYP3A4MEN1KMT2AALDH1A1 | |
| SCHEMBL15214888 | 0.81 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL18352400 | 0.81 | MEN1 (0.41) | NPSR1CYP3A4MEN1KMT2A | |
| SCHEMBL2044620 | 0.81 | NPSR1 (0.36) | NPSR1CYP3A4MEN1KMT2ACYP4F2 | |
| SCHEMBL19954966 | 0.79 | NPSR1 (0.35) | NPSR1CYP3A4MEN1KMT2ACYP4F2 | |
| SCHEMBL15214889 | 0.79 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL28319090 | 0.78 | DGAT1 (0.34) | NPSR1 | |
| SCHEMBL12385681 | 0.77 | DPP4 (0.34) | NPSR1CYP3A4MEN1KMT2AALDH1A1 | |
| SCHEMBL30602703 | 0.75 | FFAR3 (0.43) | — | |
| SCHEMBL3000663 | 0.74 | GRIN2B (0.40) | SMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170020869-A1 | Neuroprotective Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2017-01-26 | — | — | US | disclosed |
| US-20150258091-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-09-17 | — | — | US | disclosed |
| US-9119851-B2 | Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals | NEUREN PHARMACEUTICALS, LTD. (NZ) | 2015-09-01 | — | — | US | disclosed |
| US-20140309230-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2014-10-16 | — | — | US | disclosed |
| US-8791117-B2 | Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2014-07-29 | — | — | US | disclosed |
| US-8519127-B2 | Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy | NEUREN PHARMACEUTICALS LIMITED (AU) | 2013-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309230-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | GRIA2, QPCT, GRM2 | NPSR1 175/4885CYP3A4 4433/4885MEN1 3438/4885 |
| US-20170020869-A1 | Neuroprotective Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | GRIN2C, GRIN2D, GRIN2A | NPSR1 264/4885CYP3A4 4714/4885MEN1 4203/4885 |
| US-20150258091-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | GRIA2, GRIN2A, QPCT | NPSR1 254/4885CYP3A4 4791/4885MEN1 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.